Venous thromboembolism in malignancy and malignancy in venous thromboembolism

Haemostasis

Volumn 28, Issue SUPPL. 3, 1998, Pages 43-49

  Rickles, Frederick R ^a   Levine, Mark N ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Cancer; Heparin; Malignancy; Tumour; Venous thromboembolism

Indexed keywords

BCG VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PREDNISOLONE; TAMOXIFEN; VINCRISTINE;

ANTICOAGULANT THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; THROMBOGENESIS; TREATMENT PLANNING;

EID: 0032465514     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022404     Document Type: Conference Paper

References (49)

1. Sproul EE: Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Med Sci 1938;34:566.
2. Thompson CM, Rodgers RL: Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci 1952;223:469.
3. Peuscher FW: Thrombosis and bleeding in cancer patients. Neth J Med 1981;24:23-35.
4. Levine MM: Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997;78:133-136.
5. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, DePauw S: The thrombogenic effect of anticancer drug therapy in women with Stage II breast cancer. New Eng J Med 1988;318:404-407.
6. Weiss RB, Tormey DC, Holland JF, Weinberg VE: Venous thrombosis during multimodal treatment of primary breast cancer. Cancer Treat Rep 1981;65:677-679.
7. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH: Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-day chemotherapy regimen. A study of 159 patients. Cancer 1984;54:1264-1268.
8. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant chemotherapy for breast cancer. J Clin Oncol 1991;9:286-292.
9. Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J, for the National Cancer Institute of Canada Clinical Trials Group: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996;14:2731-2737.
10. Wall JG, Weiss RB, Norton L: Arterial thrombosis associated with adjuvent chemotherapy for breast cancer: a Cancer and Leukaemia Group B study. Am J Med 1989;87:501-504.
11. von Templehoff GF, Dietrich M, Hommel G, Heilmann L: Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996;14:501-504.
12. Clashen PC, van de Velde CJH, Julien JP, Florias JL, Mingolet FY: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for research and Treatment of Breast Cancer Cooperative Group Study. J Clin Oncol 1994;12:1266-1271.
13. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumours responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B16. J Clin Oncol 1990;8:1005-1018.
14. Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK: Adjuvant CMFVP and tamoxifen for postmenopausal node positive and estrogen receptor positive breast cancer patients: a South-west Oncology Group Study. J Clin Oncol 1994;12:2078-2085.
15. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. New Engl J Med 1989;320:479-484.
16. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG: Tamoxifen and chemotherapy for lymph node negative, estrogen receptor positive breast cancer. J Natl Cancer Inst 1997;89:1673-1682.
17. Rickles FR, Levine MN, Dvorak HF: Abnormalities of haemostasis in malignancy: in Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds): Haemostasis and Thrombosis: Basic Principles and Clinical Practice, 4th ed., Philadelphia, Lippincott-Raven, in press.
18. von Templehoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L: Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997;77:456-461.
19. Barbui T, Finazzi G, Grassi A, Marchioli R: Thrombosis in cancer patients treated with hematopoietic growth factors - a meta-analysis. Thromb Haemost 1996;75:68-371.
20. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C: Very low doses of warfarin can prevent thrombosis in central vein catheters: a randomized prospective trial. Ann Intern Med 1990;112:423-428.
21. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A: Upper extremity deep vein thrombosis in cancer patients with venous access devices - prophylaxis with a low-molecular-weight heparin (Fragmin). Thromb Haemost 1996;75:251-253.
22. Kakkar VV, Howe CT, Nicolaides AN, Renney JTG, Clarke MB: Deep vein thrombosis of the leg. Is there a high risk group? Am J Surgery 1970;120:527-531.
23. Claggett GP, Anderson FA, Heit J, Levine MN, Wheeler HB: Prevention of venous thromboembolism. Chest 1995;108(suppl):312-334.
24. Levine MN: Cancer patients; in Goldhaber S (ed): Prevention of Venous Thromboembolism. New York, Dekker, 1993 pp 463-483.
25. Sack GH, Levin J, Bell WR: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms. Medicine (Baltimore) 1977;56:1-37.
26. Lieberman JS, Borrero J, Urdoncta E, Wright IS: Thrombophlebitis and cancer. J Am Med Ass 1961;177:542-545.
27. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
28. Levine M, Gent M, Hirsh J, Leclere J, Anderson D, Weitz, Ginsberg J, Turpie AGG, Demers C, Kovacs M: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. New Engl, J Med 1996;334:677-681.
29. Trousseau A: Phlegmasia alba dolens; in Clinique médicale de l'Hôtel-Dieu de Paris. Paris, Ballière, 1865, vol 3, pp 654-712.
30. Luzzatto G, Schafer AI: The prethrombotic state in cancer. Semin Oncol 1990;17:147-159.
31. Levine M, Hirsh J: The diagnosis and treatment of thrombosis in the cancer patient. Semin Oncol 1990;179(suppl):160-171.
32. Monreal M, Lafoz E, Casals A, Inargaja L, Montserrat E, Callejas JM, Martorell A: Occult cancer in patients with deep venous thrombosis: a systematic approach. Cancer 1991;67:541-545.
33. Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa, ten Cate JW: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. New Engl J Med 1992;327:1128-1133.
34. Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Mundo MR: Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest 1993;103:816-819.
35. Nordstrom M, Linbald B, Anderson H, Berggvist D, Kjellstrom T: Deep vein thrombosis and occult malignancy: an epidemiological study. BMJ 1994;308:891-894.
36. Prins MH, Lensing AWA, Hirsh J: Idiopathic deep vein thrombosis. Is a search for malignant disease justified? Arch Intern Med 1994;154:1310-1312.
37. Bastounis EA, Karyiannakis AJ, Makri GG, Alexious D, Papalambrous EL: The incidence of occult cancer in patients with deep vein thrombosis: a prospective study. J Intern Med 1996;239:153-156.
38. Cornuz J, Pearson SD, Creagor MA, Cook EF, Goldman L: Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996;25:785-793.
39. Rance A, Emmerich J, Guedj C, Fiessinger J-N: Occult cancer in patients with bilateral deep-vein thrombosis. Lancet 1997;350:1448-1449.
40. Agnelli G: Venous thromboembolism and cancer: a two-way clinical association. Thromb Haemost 1997;78:117-120.
41. Prins MH, Hettiarachchi RJK, Lensing AWA, Hirsh J: Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? Thromb Haemost 1997;78:121-125.
42. Monreal M, Fernandez-Llamazares, Perandreu J, Urrutia A, Sahuquillo JC, Contel E: Occult cancer in patients with venous thromboembolism: which patients, which cancers? Thromb Haemost 1997;78:1316-1318.
43. Hettiarachchi RJK, Prins MH, Buller HR, Prandoni P, ten Cate JW: Occult malignancy in patients with deep-vein thrombosis. Incidence and risk indicators. Thromb Haemost 1997;78(suppl):383 (abstract).
44. Achkar A, Laaban JP, Horellou MH, Rabbat A, Conrad J, Nataf J, Samama MM, Rochmaure J: Prospective screening for occult cancer in patients with venous thromboembolism. Thromb Haemost 1997;78 (suppl):383 (abstract).
45. Rajan R, Levine M, Gent M, Hirsh J, Geerts W, Skingley P, Julian J: The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis. Results from a historical cohort study. Thromb Haemost 1998;79:19-22.
46. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL: The risk of a diagnosis of cancer after after primary deep venous thrombosis or pulmonary embolism. New Engl J Med 1998;338:1169-1173.
47. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M: Venous thromboembolism and cancer. Lancet 1998;351:1077-1080.
48. Barosi G, Marchetti M, Dazzi L, Quaglini S: Testing for occult cancer in patients with idiopathic deep vein thrombosis - a decision analysis. Thromb Haemost 1997;78:1319-1326.
49. Screening for occult malignant disease in patients with symptomatic idiopathic venous thromboembolism (SOMIT). Thromb Haemost 1992;68:783.